• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pediatr Infect Dis J . Rates, Risk Factors and Outcomes of Complications After COVID-19 in Children

tetano

Editor, Senior Moderator
Pediatr Infect Dis J


. 2025 May 1;44(5):449-454.
doi: 10.1097/INF.0000000000004649. Epub 2024 Dec 4. Rates, Risk Factors and Outcomes of Complications After COVID-19 in Children

Mallika Rattanawijit[SUP] 1 [/SUP], Arisara Samutpong[SUP] 2 [/SUP], Nopporn Apiwattanakul[SUP] 3 [/SUP], Surapat Assawawiroonhakarn[SUP] 4 [/SUP], Chonnamet Techasaensiri[SUP] 3 [/SUP], Sophida Boonsathorn[SUP] 3 [/SUP], Sujittra Chaisavaneeyakorn[SUP] 3 [/SUP]



Affiliations
Abstract

Background: Coronavirus disease 2019 (COVID-19) can lead to various complications, including multisystem inflammatory syndrome in children (MIS-C) and post-COVID-19 conditions (long COVID). This study aimed to determine the rates, risk factors and outcomes of MIS-C and long COVID in children previously diagnosed with COVID-19.
Methods: This study was a combined retrospective and prospective cohort study. Patients 0-18 years of age diagnosed with COVID-19 or another respiratory virus infection were enrolled between October 2021 and April 2022. Demographic and clinical data were reviewed. Information on persisting symptoms and their impacts were recorded at 1-3, 3-6 and 6-12 months after infection. Laboratory investigations and chest imaging examinations were performed during follow-up. MIS-C and long COVID were defined according to the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) definitions.
Results: A total of 618 patients were enrolled, comprising 437 (70.7%) with COVID-19 and 181 (29.3%) with another respiratory virus infection. At 1-3 months, the rate of persisting symptoms was 16.5% in patients with COVID-19, compared with 1.1% in patients with another respiratory virus infection. The rate of MIS-C was 0.7%. The rate of long COVID according to the CDC and WHO definitions were 20.4% and 13.0%, respectively. Respiratory systems were most affected in long COVID. Age 5-18 years, anosmia during COVID-19, history of pneumonia and infection during the delta and omicron waves were associated with long COVID in children.
Conclusions: Long COVID after COVID-19 in children is uncommon. Children with anosmia and a history of pneumonia during COVID-19 require follow-up for long COVID.

Keywords: COVID-19; children; long COVID; multisystem inflammatory syndrome in children; post-COVID-19 conditions.

 
Back
Top Bottom